Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com
All News
ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.
The current JAMA Pediatrics issue has published a report showing that adjunctive corticosteroid therapy yielded significantly fewer coronary artery complications compared with intravenous immunoglobulin therapy alone, particularly among high-risk patients with Kawasaki disease.
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.
In this video, Michelle Petri, MD, director of the Hopkins Lupus Center at Johns Hopkins University, discusses recent successes and challenges in the treatment of systemic lupus erythematosus, with clinical trials results ranging from "wildly positive" to "completely negative."
RheumNow will periodically review this subject with “Biosimilar Reports” providing updates, news, new publications, overview articles and research results impacting to biosimilar development and use.
Children with juvenile idiopathic arthritis (JIA) treated with biologic therapies were at no higher risk for hospitalized infections than those treated with methotrexate alone, But, higher rates were seen with anakinra in systemic JIA.
Singh and colleagues have published a systematic review and Bayesian network metaanalyses of clinical trials of immunosuppressive drugs and corticosteroids in patients with lupus nephriti.
A Wall Street Journal article claims that U.S. drugmakers are pointing the blame at the middlemen who also influence drug priciing.
Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.
Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year.
Three new FDA approvals, proteomics, cancer, infectious risk, nonadherence and disappointing clinical trial results covered in this RheumNow Week in Review.
Rates of serious infection and mortality among patients with systemic lupus erythematosus (SLE) did not depend on the immunosuppressive drug regimen they were on, investigators reported.
Ilaris was previously approved for use in systemic JIA and CAPS. The FDA has expanded this to include TRAPS, Hyper-IgD and FMF based on clinical trials.
2016 has been a big year for biosimilars in rheumatology.
The anti-IL-12/IL-23 inhibitor, Stelara (ustekinumab) has been FDA approved for the treatment of psoriasis and psoriatic arthritis. In the last week, the EMA's CHMP has recommended that the drug also be approved for use in Crohn's disease.
Who makes billions in profits and millions in bonus monies? PBMs and insurers, thats who.
This week United Healthcare and Express Scripts announced new plans to restrict patient and prescriber access to popular, expensive, albeit FDA-approved, medications and biologics.
Who benefits, who loses?
